Exosome and Extracellular Vesical-Based Therapeutics

12th November 2021
Abstract It was previously believed that exosomes, membrane-bound extracellular vesicles released by cells, were a waste disposal mechanism resulting from cell damage or from by-products of cell...
Learn More

The emerging landscape of RNA-targeted small molecules

17th September 2021
Intro: For decades, conventional drug strategy has relied on the ability of small molecules to either inhibit or alter protein function by targeting their active sites. While this was instrumental in...
Learn More

Replacing the Surrogates: Beyond In Vivo Preclinical Models | Preclinical Development

24th August 2021
Intro: Animal modelling is a staple of preclinical drug development and in most countries a legal requirement before entering human trials. However, these experiments are time-consuming, expensive,...
Learn More

What's on Pharma's Licensing Wish List?

04th August 2021
Asset licensing, mergers, and acquisitions have become an integral pipeline expansion strategy for Pharma. The realization over the past two decades that productivity of internal R&D alone is...
Learn More

Cell Therapy for Autoimmune Disease: Landscape Analysis & Overview

01st February 2021
The cell therapy field has been predominantly active in the oncology space and is enjoying bench-to-bedside clinical success. However, the cancer cell therapy space has become very crowded and drug...
Learn More

Cellular Immunotherapy: Challenges and Potential Solutions

18th August 2020
It would not be an overstatement to say that in recent years cellular immunotherapies have demonstrated great therapeutic success in some cancers. However, several technical difficulties remain that...
Learn More

An Analysis of the Cellular Immunotherapy Landscape for Cancer

20th June 2020
Types of cellular immunotherapy:  Cellular immunotherapies involve modifying autologous or allogeneic immune cells through genetic engineering or modulation of the protein expression profile, then...
Learn More

A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome

11th November 2019
The purpose of this analysis of patient-reported outcomes from the ELECT (Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment) trial (NCT00774930) was to...
Learn More

Valuing Pharmaceutical Assets: When to Use NPV vs rNPV

15th October 2019
Preview: A variety of approaches have been developed to evaluate pharmaceutical assets, but two similar yet distinct methods are most commonly used. Venture capitalists and large investment firms...
Learn More

Adeno-Associated Virus Gene Therapy Landscape

24th September 2019
Adeno-associated viruses (AAV) are virus particles composed of single-stranded DNA surrounded by a protein shell. Despite their simple structure, recombinant AAVs (rAAV) can perform the important...
Learn More

Pharma Due Diligence: General Guidance & Common Pitfalls

23rd August 2019
The Basics Due diligence, the formal exercise of quantifying risks and confirming value, has been described as “Art meets Science” and there’s a lot of truth in that. To some, it’s simply a question...
Learn More

FDA Expedited Programs for Cancer Drug Development: Don’t Believe the Doubters

16th August 2019
Intro:  
Learn More
1 2 3